Analytik Jena Increases Stake in AJ Innuscreen to 100 %

Jena, January 10, 2011 ? Analytik Jena AG (Frankfurt DE0005213508, Prime Standard: AJA) has increased its stake in subsidiary AJ Innuscreen GmbH to 100.0% and is now its sole owner. Thus, the Jena-based manufacturer of analytical instrumentation technology is continuing its strategic course of stepping up its life cycle business.

"With its high level of investment in the molecular diagnostics segment, AJ Innuscreen is making a major contribution towards establishing the Life Science division. Increasing our shareholding enables us to integrate our subsidiary more closely into the Group and expand the synergies in our growth segment,” said Klaus Berka, CEO of Analytik Jena AG.

AJ Innuscreen develops and manufactures products for the isolation and purification of nucleic acids as well as innovative rapid tests for molecular diagnostics. The Analytik Jena subsidiary was founded in 2005 with the aim of expanding and strengthening the Life Science division within the Group. A total of 19 patents have been registered since it was founded. In the 2009/2010 financial year the company, which is headquartered in Berlin-Buch, generated sales of around EUR 1.7 m and achieved a positive result. The product portfolio currently comprises 168 products for nucleic acid isolation, molecular biological enzymes and diagnostic assays.